Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5

Autor: Parker, Maria A., Erker, Laura R., Audo, Isabelle, Choi, Dongseok, Mohand-Said, Saddek, Sestakauskas, Kastytis, Benoit, Patrick, Appelqvist, Terence, Krahmer, Melissa, Ségaut-Prévost, Caroline, Lujan, Brandon J., Faridi, Ambar, Chegarnov, Elvira N., Steinkamp, Peter N., Ku, Cristy, da Palma, Mariana Matioli, Barale, Pierre-Olivier, Ayelo-Scheer, Sarah, Lauer, Andreas, Stout, Tim, Wilson, David J., Weleber, Richard G., Pennesi, Mark E., Sahel, José Alain, Yang, Paul
Zdroj: In American Journal of Ophthalmology August 2022 240:285-301
Databáze: ScienceDirect
Externí odkaz: